Q1 2020 Astellas Pharma Inc Earnings Call Transcript
Once again, I'm Takeda. Thank you very much, indeed, for participating in this conference call today. I spend about 20 to 30 minutes to give you an overview of the financial results and explain our initiatives for sustainable growth.
Please turn to Page 4. Q1 fiscal year 2019 financial results on a core basis. Let me give you an overview. On a consolidated basis, revenues increased to JPY 334.1 billion, up 1.5% year-on-year. Core operating profit increased by 0.8% to JPY 84.7 billion. Core profit for the period was 67.1% (sic) [JPY 67.1 billion], down 4.6% year-on-year. Corporate tax rate increased from the previous year. There were one-off special items in the previous fiscal year. The corporate tax rate was low. As a result, the corporate tax rate rose year-on-year. Core operating profit increased to this level, but the higher corporate tax rate led to a decrease in the core profit for the period. Core EPS was remaining flat, minus 4.6% (sic) [minus 0.3%] year-on-year. A decrease in quarterly profit was offset by the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
